Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)
- Authors
- Sun, M.; Spigel, D. R.; Lee, Y-J.; Yoon, H.; Liu, Y.; Ahern, E.; Harris, S.; Lee, G-W.; Yan, D.; Chen, J.; Shiah, H-S.; Deng, T.; Zheng, H.; Tan, W.; Zhou, Z.; Wang, R.; Ba, Y.
- Issue Date
- Oct-2023
- Publisher
- Oxford University Press
- Citation
- Annals of Oncology, v.34, pp S862 - S863
- Indexed
- SCIE
SCOPUS
- Journal Title
- Annals of Oncology
- Volume
- 34
- Start Page
- S862
- End Page
- S863
- ISSN
- 0923-7534
1569-8041
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.